TVRD - Tvardi Therapeutics, Inc. Common Stock
| Day | 1m | 10m | 60m | PreMarket | Market | AfterHours | Gap |
|---|---|---|---|---|---|---|---|
| 6.91 -0.37 (-5.35%) | --- | --- | --- | -0.1 (-1.45%) | -0.23 (-3.33%) | -0.04 (-0.54%) | -0.04 (-0.54%) |
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
Category:
PHARMACEUTICAL PREPARATIONS
Market Period:
AfterHours
Earnings & Ratios
- Basic EPS:
- 0.51
- Diluted EPS:
- -1.0
- Basic P/E:
- 12.8235
- Diluted P/E:
- -6.54
- RSI(14) 1m:
- 57.14
- VWAP:
- 6.54
- RVol:
- 1.5566
Events
| Period | Kind | Movement | Occurred At |
|---|---|---|---|
| 1m | Price increase 1m | 6.63 +0.09 (+1.38%) | Oct 15 16:26 |
| 1m | Price decrease 1m | 6.61 -0.12 (-1.78%) | Oct 15 15:47 |
| 1m | Price decrease 1m | 6.74 -0.08 (-1.25%) | Oct 15 15:43 |
| 1m | Price increase 1m | 6.82 +0.08 (+1.19%) | Oct 15 15:41 |
| 1m | Price increase 1m | 6.78 +0.11 (+1.58%) | Oct 15 15:39 |